Intravitreal bevacizumab and diabetic papillopathy with macular edema.

Sir,

The recent publication on intravitreal bevacizumab and diabetic papillopathy with macular edema is very interesting.[1] Al-Hinai et al., conclude that “bevacizumab is a useful treatment in diabetic papillopathy by shortening the duration of the course of the disease”.[1] It might seem that this treatment is effective. However, there are many things to be discussed. Experience of the practitioner is very important and there are some reports on complications of this practice.[23] The observation on systemic change corresponding to the use of bevacizumab is also required.[4] Finally, although bevacizuman is more effective than simple triamcinolone acetonide,[5] the question of cost needs to be researched.